NETRF receives $5 Million from the Margie and Robert E. Petersen Foundation Annual NETRF research symposium to be named in their honor
Earlier this month, NETRF announced it received a $5 million endowment gift from The Margie and Robert E. Petersen Foundation. This gift brings NETRF’s 2021 fundraising total to $7.26 million to fund NET research around the globe.
Automobile publishing giant Robert E. Petersen passed away in 2007 from neuroendocrine cancer, which is diagnosed in an estimated 12,000 Americans each year. The disease also claimed the lives of Apple founder Steve Jobs and legendary performer Aretha Franklin.
| |
New Phase II Alpha-emitter clinical trial
A new phase II clinical trial is evaluating the safety and effectiveness of 212Pb-DOTAMTATE in patients who have somatostatin receptor-expressing neuroendocrine tumors but who have not received peptide receptor radionuclide therapy, or PPRT.
The study, called ALPHAMEDIX02, has opened at Excel Diagnostics and Nuclear Oncology Center in Houston and the principal investigator is Rodolfo Nunez, MD. The ALPHAMEDIX02 clinical trial will measure the response rate of treatment with the alpha-emitter therapy with 212Pb-DOTAMTATE (also called AlphaMedix™) as well as measure progression-free survival, overall survival, and the length of time to tumor progression. Read more here.
| |
|
There's still time to apply for 2022 NETRF Grant Funding
The Neuroendocrine Tumor Research Foundation (NETRF) invites researchers to respond to the 2022 Request for Applications. To learn about NETRF’s funding opportunities go here.
NETRF invites transformative basic, translational, and clinical research applications with the potential to advance our understanding of neuroendocrine tumors and their treatment.
Grants range from $100,000 to $1.2 million USD, with specific opportunities for early career investigators. For 2022 Program Guidelines/Eligibility Criteria and to start a 2022 NETRF grant application click here.
| |
NETWise Podcast: Focus on Liver NETs
Learn more about liver NETs in the next NETWise podcast, coming later this week. The liver is the first and most significant site of neuroendocrine tumor metastasis and for many people, managing liver tumors is the most challenging part of NET treatment. In this episode, you’ll hear from physicians about why your liver is a remarkable organ and the treatment options for liver NETs. Plus, people with liver NETs share their experience and perspective. Check out NETWise here or sign up for our podcast notification.
| |
Treatment sequencing for NETs
One of the most frequent questions from NET patients is about treatment sequencing—which treatments are effective and in which order? The answer is often complicated and individualized. Check out this panel of experts discussing treatment sequencing, at NETRF’s KNOW YOUR NETs Virtual Patient Conference, featuring Xavier Keutgen, MD, Osmanuddin Ahmed, MD, and Chih-Yi “Andy” Liao, MD, all from the University of Chicago Medicine; Erik Mittra, MD, PhD, of Oregon Health & Science University; and Thor Halfdanarson, MD, of the Mayo Clinic. Watch here.
| |
Todd Gilman elected President, NETRF Board of Directors
Past President Joe Li, MD, recognized for his outstanding leadership
Todd Gilman, a long time NETRF board member, has been elected president at the Board’s January meeting. He succeeds Joe Li, MD, who has served as
president since 2017. Read more here.
| |
Welcome Suzanne Ludlow
NETRF is thrilled to welcome patient education and access advocate Suzanne Ludlow to its Board of Directors. After losing her husband to neuroendocrine cancer, Suzanne became involved with NETRF and graciously funded the NETRF Neuroendocrine Cancer Guide for Patients & Families. Read more about Suzanne here.
| |
It's that time of year....
Gathering all your paperwork to file your taxes? At NETRF, we are incredibly grateful for the support of our generous donors. Should you need a copy of your official NETRF acknowledgment of your 2021 gift, please email Susan Payson or Eva May for a copy of your donation paperwork and receipt. And as always, thank you!
| |
Wrap Your Caregiver in Love Support NET Research with a Love Note Gift
There's still time to recognize that special someone! Supporting, advocating, and caring for a person with a cancer diagnosis is not a job for the weak of heart. Yet, it’s a calling that spouses, partners, siblings, parents, children, aunts, uncles, and friends courageously answer every day for the loved ones in their lives diagnosed with neuroendocrine cancer (NETs).
We invite you to express your love and gratitude to those in your family or community who care for you through a Love Note gift. Leave a message about why they mean the world to you and NETRF will send your message along with a Love Note to the person who has been by your side every step of the way. This is a beautiful way to donate to NET research while recognizing those who give you a sense of hope. Write your Love Note here.
| |
Remembering a NET Champion
With sadness, we note the passing of a giant in the NET world, Dr. Tom “ODO” O’Dorisio. Dr. O'Dorisio died peacefully at home in Ohio on February 2. Dr. O’Dorisio was an internationally respected expert in NETs, known for his stories, his wit, and his positive spirit.
He joined the University of Iowa in 1999, after many years at his alma mater, Ohio State University, where he held appointments in Internal Medicine, Physiology, and Pathology and Human Nutrition. In 2015, Drs. Tom and Sue O'Dorisio were instrumental in obtaining an NIH Specialized Program of Research Excellence (SPORE) grant for the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa to address neuroendocrine tumors. Four years later, with their leadership, the HCCC earned a Center of Excellence designation from the European Neuroendocrine Tumor Society (ENETS). HCCC is the only ENETS certified center in the United States. In 2017, Dr. ODO was chosen, along with Dr. Sue O'Dorisio, as the recipient of NANETS' Lifetime Achievement Award.
We extend our sympathies to Dr. Sue O’Dorisio and family, and to all who called Dr. ODO friend, colleague, and trusted physician.
| |
Special thanks to Advanced Accelerator Applications for sponsoring this February E-update.
| |
|
|
|
|
